Pharmac's set-up risks higher health costs: medicines research

Pharmac's set-up risks higher health costs: medicines research
New Zealand's spending on modern pharmaceuticals sits far below comparable OECD countries. (Image: NZIER for Medicines NZ)
Pattrick Smellie
The Government's drug-buying agency, Pharmac, is being criticised for its inability to drive hard bargains with Big Pharma, which may be restricting New Zealanders’ access to modern medicines and driving demand for high-cost hospital care.Those are primary conclusions of research for Medicines New Zealand by the NZ Institute of Economic Research (NZIER), examining why NZ’s national pharmaceutical spend is among the lowest in the rich countries club, the Organisation for Economic Cooperation and Development (OECD).The study concl...

More Economy

An alternative to asset sales
Opinion

Cameron Bagrie: An alternative to asset sales

The case for outsourcing management of government assets. 

Cameron Bagrie 12 Nov 2025
BNZ looks to economic uptick supporting its full year 2026 outturn
Finance

BNZ looks to economic uptick supporting its full year 2026 outturn

BNZ is the latest bank to cautiously spruik GDP growth in 2026.

Andy Macdonald 07 Nov 2025
RBNZ says risks linked to new mortgage lending contained
Economy

RBNZ says risks linked to new mortgage lending contained

House prices near the top of RBNZ's range of sustainable estimates.

Staff reporters 06 Nov 2025
‘Remarkable growth’: Fulton Hogan posts higher profit
Economy

‘Remarkable growth’: Fulton Hogan posts higher profit

Fulton Hogan paid a total dividend of $180.4m for 2025.

Duncan Bridgeman 05 Nov 2025